
TV STARS WALK THE WALK FROM COAST TO COAST AT PANCAN PURPLESTRIDE, THE ULTIMATE WALK TO END PANCREATIC CANCER
Reality Star Joan Vassos, 'Star Trek' Team, Days of our Lives' Martha Madison & Cast Members and Lisa Niemi Swayze Take Steps to Raise Funds and Awareness for Pancreatic Cancer
LOS ANGELES, April 28, 2025 /PRNewswire/ — This past Saturday, April 26, the Pancreatic Cancer Action Network (PanCAN) held its biggest fundraising event of the year, PanCAN PurpleStride, the ultimate walk to end pancreatic cancer. PanCAN PurpleStride took place nationwide in nearly 60 cities as survivors, supporters, celebrities and special guests walked in solidarity to raise awareness and much-needed funds for pancreatic cancer, one of the world's deadliest forms of cancer. It is the number one way PanCAN raises funds to fuel its mission and the dollars raised change the lives of people facing pancreatic cancer and advance progress against the disease. Nearly 63,000 people across the country attended, raising nearly $16.5 million towards fighting the disease.
Pancreatic cancer remains the third leading cause of cancer-related deaths in the United States and is on track to become the second leading cause. It is the only major cancer with a five-year survival rate below 20%. Because symptoms are often vague and mimic other illnesses or conditions, most patients are diagnosed in the late stages of the disease. There is no standard screening strategy for pancreatic cancer and few treatment options, highlighting the urgent need for increased research, funding and awareness to improve patient outcomes.
'You are supporting PanCAN's critical work – giving patients and caregivers the resources and knowledge they need to navigate this disease through PanCAN Patient Services; funding research to find a way to detect this disease earlier and find better treatments for patients; and advocating for more federal funding for this disease because we know science follows money,' said Julie Fleshman, JD, MBA, president and CEO, PanCAN at PurpleStride Los Angeles' opening ceremony. 'Events like PurpleStride are more important than ever right now because of recent cuts to federal funding for pancreatic cancer research. We desperately need both public and private funding for this disease to ensure scientists have the resources they need to drive progress and improve patient outcomes, so thank you again for being here today and taking action.'
From coast to coast and across the television spectrum, notable figures joined the fight. Joan Vassos was a featured speaker at PurpleStride Washington D.C., while actors from Star Trek, including Kitty Swink, John Billingsley, and TV writer-producer Juan Carlos Coto, who lost his brother, 'Star Trek Enterprise' Executive Producer Manny Coto, to the disease, along with Lisa Niemi Swayze and Days of our Lives' Martha Madison and many of the cast of the show participated in PurpleStride Los Angeles.
'PanCAN provides critical resources, research, and support—and in doing so, gives the one thing John clung to most: hope,' said Joan Vassos. 'I walk in honor of John, alongside family and friends as Team 'It's Just a Sprain,' and I advocate so that no other family has to go through this terrible journey alone.'
Notable celebrities showed up to walk and support PanCAN's mission in several cities across the country:
At PurpleStride Washington D.C, Reality star and advocate, Joan Vassos led her team 'It's Just A Sprain' in honor of her late husband, John, who passed away from the disease in 2021.
At PurpleStride Los Angeles, Daytime TV stars Martha Madison from Days of our Lives and many of the Days' cast members formed their own PurpleStride team, 'Hogey's Home Runners' in honor of TV's greatest hero—and their on-screen dad—Drake Hogestyn, who portrayed John Black. After losing Drake to pancreatic cancer, they came together at PurpleStride Los Angeles to raise funds and awareness in his memory.
Other notable celebrities at PurpleStride Los Angeles included:
Lisa Niemi Swayze: Writer, director, actress, dancer and wife of the late actor, Patrick Swayze, who passed from pancreatic cancer. Lisa cut the purple ribbon at PurpleStride Los Angeles. Star Trek Team: Once again leading the charge for team 'Trek Against Pancreatic Cancer' are the inspiring Kitty Swink, a 21-year pancreatic cancer survivor from 'Deep Space Nine', John Billingsley ('Star Trek: Enterprise') and TV writer-producer Juan Carlos Coto, who lost his brother, 'Star Trek Enterprise' Executive Producer Manny Coto, to the disease. This dedicated team boldly went where they've gone before and participated in their fifth PanCAN PurpleStride! Rosa Blasi, Actress ('The Thundermans') 'Days of Our Lives' cast members including: Brandon Beemer, Raven Bowens, Heather Boyd, Rachel Boyd, Bryan Datillo, Kennedy Garcia, Alice Halsey, Tina Huang, Cherie Jimenez, Abigail Klein, Victoria Konefal, Dan Feuerriegel, John Paul Lavoisier, Stephen Nichols, Shi Ne Nielson, Ashley Puzemis
Notable individuals who have succumbed to pancreatic cancer in recent years include Jeopardy! host Alex Trebek, talk show host Jerry Springer, Supreme Court Justice Ruth Bader Ginsburg, producer Quincy Jones and U.S. Representative John Lewis, to name a few
Donations can still be made by visiting purplestride.org. PanCAN PurpleStride is generously supported by leading national partner, Revolution Medicines, and national sponsors Ipsen and AbbVie. For more information about the Pancreatic Cancer Action Network and its urgent mission to save lives, visit pancan.org or follow PanCAN on X, Instagram, and Facebook.
The Pancreatic Cancer Action Network (PanCAN) is the leading organization dedicated to advancing progress against pancreatic cancer. We empower patients and caregivers with the resources and knowledge they need to advocate for the care they deserve; we are pioneering the advancement of an early detection strategy for pancreatic cancer and revolutionizing the development of advanced and personalized treatments; and we are building and mobilizing the pancreatic cancer field to ensure better outcomes for all those who face pancreatic cancer today and all those who will fight this disease tomorrow.
Media Contacts:Stephanie Berman, Smithhouse Strategy, 917-617-5667, stephanie@smithhousestrategy.comJulie Vasquez, PanCAN, 310-697-9129, jvasquez@pancan.org
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Malaysian Reserve
15 hours ago
- Malaysian Reserve
9th Asia Agri-Tech Expo & Forum Opens Today, Driving Innovation in Asia-Pacific Agriculture
TAIPEI, June 11, 2025 /PRNewswire/ — Organised by Informa Markets Asia Ltd., the 2025 Asia Agri-Tech Expo & Forum officially opened today (June 11) at the ICC Tainan. The grand opening ceremony gathered key representatives from government, industry, academia, and research to witness a new milestone in the advancement of agri-tech in the Asia-Pacific region. Distinguished guests attending the ribbon-cutting ceremony included Mr. Michael Duck, Executive Vice President of Informa Markets Asia, Deputy Mayor Yeh Tse-Shan of Tainan City Government, President Su Chih-Fen of the National Animal Industry Foundation, along with numerous prominent figures from various sectors. This year's event features over 150 exhibitors from around the world, showcasing cutting-edge innovations in agriculture automation, smart livestock farming, precision irrigation, crop monitoring, and feed technology. In addition to the exhibition, the event presents 10 key themes across 60 professional seminars, offering in-depth discussions on emerging trends in agriculture, smart livestock farming, advanced feed technology, and biosecurity upgrades. The three-day exhibition is expected to attract over 25,000 visitors. With Tainan serving as a central hub for agriculture and aquaculture in southern Taiwan, the event provides an ideal platform for farmers, growers, and industry professionals to explore the latest advancements. Many exhibitors are launching new products on-site, including: TOTAL NUTRITION: Combining peptide protein, probiotics, and acidifiers to form the 'Golden Triangle' of gut health, achieving precise nutritional regulation and enhanced well-being. WONDER VAX: Introducing the Universal Live Vaccine for Infectious Bronchitis in Chickens (TW-I, TW-II), providing dual protection against respiratory and nephritis strains, precisely targeting Taiwan's prevalent local strains (TW-I, TW-II). YA SUH DAR: Launching a 50-inch butterfly shutter exhaust fan specifically designed for livestock farming. This large negative-pressure fan features an innovative pneumatic butterfly shutter design that effectively replaces traditional louver windows, significantly improving ventilation efficiency. It also offers excellent dustproof, corrosion-resistant, and weather-resistant performance, making it ideal for harsh environments with high temperatures and humidity. VETNOSTRUM: Comprehensive range of veterinary medicines, health products, feed additives, and feeds for pigs, cattle, sheep, poultry, and aquatic animals. AGRISTAR: Asia's first fully electric tractor, manufactured by Foxconn in the U.S., featuring Tesla technology and NVIDIA AI computing. Compatible with a variety of agricultural implements, it serves not only in dairy farming but also in a wide range of daily agricultural and livestock operations. This next-generation farming equipment paves the way for a net-zero carbon, sustainable agricultural future. Ms. Grace Lee, General Manager of Informa Markets Taiwan, stated: 'Taiwan's agricultural sector boasts strong technological capabilities. Through this international platform, we foster knowledge exchange and drive innovation, enhancing global food self-sufficiency where Taiwan will play an increasingly pivotal role.' The expo runs from June 11 to 13, open to industry professionals and related personnel free of charge. The organizers aim to foster cross-border collaboration and create a prosperous future for Asia-Pacific agriculture, paving the way for the next century of agricultural innovation.


Malaysian Reserve
15 hours ago
- Malaysian Reserve
MPF Rebuilds and Reimagines My QuitBuddy as the Nation's Leading Digital Cessation Companion
SYDNEY, June 11, 2025 /PRNewswire/ — On World No Tobacco Day, Miroma Project Factory (MPF) launched the next evolution of My QuitBuddy, Australia's flagship smoking and vaping cessation app, commissioned by the Department of Health, Disability and Ageing. The My QuitBuddy app aims to help Australians kick the habit for good. Modernised, rebuilt, and ready to support a new generation of quitters, this multi-phase redevelopment is the most significant upgrade in the app's history. MPF has led the product redesign, technical delivery, and strategic roadmap across seven structured phases – replatforming, refreshing, and relaunching a vital public health tool for the digital age. 'The My QuitBuddy app has already helped more than 1 million Australians quit smoking and vaping since it was first released in 2012, and the new developments will make it even easier for people to kick the habit,' said Mark Butler, Minister for Health, Disability and Ageing. The upgraded app is part of a suite of measures the Australian Government has put in place to tackle the health scourge of tobacco and nicotine use, particularly to support priority populations such as young people to quit smoking and vaping.' Originally launched in 2012 to support a broad range of smokers, My QuitBuddy has evolved to address broader and more complex needs, including support for people who vape. The app features stronger motivational goal setting, badges and achievements, challenges for testing situations and a more intuitive user experience; all designed to make quitting feel more achievable – and more personal. MPF was first engaged in late 2023, to reimagine the journey to be smoke/vape free, initially to restore the Android version of My QuitBuddy. This was followed by five additional phases from stabilising the app and migrating to a new environment (Flutter), which laid the foundation for a modern, cross-platform foundation without altering core functionality. Launching today marks the most transformative release that MQB has gone through. A full reimagining of the app with multiple quit pathways, advanced tracking, enhanced gamified features, dynamic onboarding, and personalised messaging for a wide range of users. 'Every click, swipe, and prompt in My QuitBuddy 2.0 is grounded in behavioural science and backed by deep user insight,' said Kat Robinson, Global CEO of MPF. 'We're not just building a better-looking app, we're building a better quit journey for every Australian.' Built for Real Impact and Reach The updated My QuitBuddy app has been shaped by years of behavioural insights, user testing, and direct feedback from the quitting community. From cravings to milestones, every screen is designed to support users when it matters most – without judgment, pressure, or gimmicks. The result is a flexible, evidence-informed platform that encourages long-term behaviour change while generating meaningful insights into user engagement, relapse patterns, and help-seeking behaviours. These insights not only guide future improvements but also provide public health teams with a clearer understanding of how different quit strategies perform across priority populations, including young vapers, dual users, and those using NRT (Nicotine Replacement Therapy) as part of their quitting strategy. Whether users are quitting cold turkey, tapering off, or using NRT, My QuitBuddy now offers them tailored support, contextual encouragement, and real-time tools to track progress, celebrate wins, prove their resilience and recover from slips. Features include: Daily motivational messages and nudges, related to your personal circumstances Richer community features and reactions, with selected featured messages Challenges you can set for yourself Games and distractions to help with cravings or withdrawal symptoms Achievements and badges that recognise how far you have come The app's new pathway selections support complex quit journeys – including simultaneous smoking and vaping cessation or staggered approaches – ensuring each user receives a personal, adaptive experience from day one. MPF now turns their efforts to continual support, enhancement, and performance monitoring. My QuitBuddy is positioned to remain a world-class cessation tool – stable, scalable, and ready to adapt with evolving policy and public health needs. Backed by MPF's long-standing partnership with the Department of Health, Disability and Aging; My QuitBuddy is more than a support app – It is a model for meaningful digital health tools, practical, evidence-based, and deeply human. DOWNLOAD ANDROID HERE DOWNLOAD IOS HERE About My QuitBuddy My QuitBuddy is a free smoking and vaping cessation app funded by the Australian Government and developed by Miroma Project Factory. Since 2012, the app has supported millions of Australians on their quit journey. Now fully rebuilt with advanced personalisation, flexible quit pathways, and updated gamified elements, My QuitBuddy is one of the most comprehensive digital cessation tools available. About Miroma Project Factory (MPF) MPF is a multi-award-winning digital strategy and product studio that delivers innovative digital solutions across web, platforms, and systems. Specialising in purposeful technology, MPF works at the intersection of strategy, design, and engineering to create impactful digital products for organisations ready to lead. With deep expertise in healthcare, MPF helps clients scale responsibly, communicate clearly, and connect meaningfully with their audiences. For more information, read about My QuitBuddy here. Press Contact:Miroma Project Factoryinfo@


Malaysian Reserve
17 hours ago
- Malaysian Reserve
Kelun-Biotech Announces Breakthrough Therapy Designation Granted for Sacituzumab Tirumotecan (Sac-TMT) in Combination With Tagitanlimab in China for Certain Types of Non-Small Cell Lung Cancer
CHENGDU, China, June 10, 2025 /PRNewswire/ — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the 'Company') today announced that its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) (佳泰莱®) in combination with the PD-L1 monoclonal antibody tagitanlimab (科泰莱®) was granted Breakthrough Therapy Designation by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China for the first-line treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) without actionable genomic alterations. Breakthrough Therapy Designation is granted for treatment options that demonstrate significant clinical advantages over currently available treatments and is aimed at expediting the research, development and marketing of innovative treatment options that address clinically urgent medical needs. This designation is based on the efficacy and safety data from the non-squamous cohort of the Phase II OptiTROP-Lung01 study. This marks the fifth Breakthrough Therapy Designation granted to sac-TMT by the NMPA. Sac-TMT has previously received this designation for: Locally advanced or metastatic triple-negative breast cancer (TNBC) in July 2022; EGFR-mutant, locally advanced or metastatic NSCLC after progression on EGFR-TKI therapy in January 2023; Locally advanced or metastatic hormone-receptor positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer (BC) in patients who have previously received at least two lines of systemic chemotherapy in June 2023; First-line treatment of unresectable locally advanced, recurrent or metastatic PD-L1 negative TNBC in March 2024. Results from a Phase 2 OptiTROP-Lung01 study of sac-TMT in combination with tagitanlimab in first-line advanced or metastatic non-squamous NSCLC patients were presented in a poster session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting[1]. Dr. Michael Ge, CEO of Kelun-Biotech said, 'This designation by the NMPA highlights the importance of developing novel therapeutic options for diverse NSCLC subtypes. Sac-TMT in combination with tagitanlimab demonstrated clinically meaningful outcomes in key endpoints for patients with non-squamous NSCLC without actionable genomic alterations as a first-line treatment. We are excited about the therapeutic potential of TROP2 ADC- immunotherapy combinations, and we look forward to working with regulatory authorities in China to bring this combination therapy to patients in need as soon as possible.' [1] Abstract #8529: Lung Cancer – Non-Small Cell Metastatic, ASCO Annual Meeting, 2025 About sac-TMT (佳泰莱®)Sac-TMT, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, BC, gastric cancer (GC), gynecological tumors, among others. Sac-TMT is developed with a novel linker to conjugate the payload, a belotecan-derivative topoisomerase I inhibitor with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells. In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc., Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (includes Mainland China, Hong Kong, Macao, and Taiwan). To date, two indications for sac-TMT have been approved and marketed in China for the treatment of adult patients with unresectable locally advanced or metastatic TNBC who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting) and EGFR mutation-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-TKI therapy and platinum-based chemotherapy. Sac-TMT became the first domestic ADC with global intellectual property rights to be fully approved for marketing. It is also the world's first TROP2 ADC to be approved for marketing in a lung cancer indication. In addition, two new indication applications for sac-TMT for the treatment of adult patients with EGFR-mutant locally advanced or metastatic NSCLC who progressed after treatment with EGFR-TKI therapy and with unresectable locally advanced, metastatic HR+/HER2- BC who have received prior endocrine therapy and other systemic treatments in the advanced or metastatic setting were accepted by the CDE, and were included in the priority review and approval process. As of today, the Company has initiated 8 registrational clinical studies in China. MSD has initiated 14 ongoing Phase 3 global clinical studies of sac-TMT as a monotherapy or with pembrolizumab2 or other agents for several types of cancer. These studies are sponsored and led by MSD. About Tagitanlimab (科泰莱®)Tagitanlimab is the first PD-L1 mAb globally to receive authorization for the first-line treatment of NPC. Previously, the NMPA has approved the marketing in China of tagitanlimab used in combination with cisplatin and gemcitabine for the first-line treatment of patients with R/M NPC and monotherapy for the treatment of patients with recurrent or metastatic NPC who have failed after prior 2L+ chemotherapy, respectively. About Kelun-BiotechKelun-Biotech ( is a holding subsidiary of Kelun Pharmaceutical ( which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. The company focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. The Company is committed to becoming a leading global enterprise in the field of innovative drugs. At present, the Company has more than 30 ongoing key innovative drug projects, of which 3 projects have been approved for marketing, 1 project is in the NDA stage, and more than 10 projects are in the clinical stage. The company has established one of the world's leading proprietary ADC platforms, OptiDC™, and has 1 ADC project approved for marketing, 1 ADC project in NDA stage, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit Media: klbio_pr@